TSHA — Taysha Gene Therapies Share Price
0.000.00%
Last trade - 00:00- $529.04m
- $434.72m
- $8.33m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 7.4 | ||
| Price to Tang. Book | 7.4 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 63.49 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -68.18% | ||
| Return on Equity | -121.94% | ||
| Operating Margin | -1097.55% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | 2.5 | 15.45 | 8.33 | 6.71 | 4.43 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Taysha Gene Therapies Inc is a clinical-stage biotechnology company, which is focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. The Company’s lead clinical program, TSHA-102, is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder. The Company is evaluating TSHA-102 in the REVEALPhase I/II adolescent and adult clinical trial, which is a first-in-human, open-label, randomized, dose escalation and dose-expansion, multicenter study evaluating the safety and preliminary efficacy of TSHA-102 in female patients aged 12-years and older with Rett syndrome. It has acquired a worldwide right to a clinical-stage, intrathecally dosed AAV9 gene therapy program, TSHA-120, for the treatment of giant axonal neuropathy (GAN). TSHA-105 is a gene replacement therapy in development for the treatment of SLC13A5 deficiency, a rare autosomal recessive epileptic encephalopathy.
Directors
- Ra Session PRE (42)
- Kamran Alam CFO (43)
- Suyash Prasad OTH (50)
- Phillip Donenberg IND (60)
- Paul Manning IND (65)
- Sukumar Nagendran IND (55)
- Sean Nolan IND (53)
- Kathleen Reape IND (55)
- Laura Sepp-Lorenzino IND (60)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- February 13th, 2020
- Public Since
- September 24th, 2020
- No. of Shareholders
- 38
- No. of Employees
- 73
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 205,054,570
- Address
- 3000 Pegasus Park Drive, Suite 1430, DALLAS, 75247
- Web
- https://tayshagtx.com/
- Phone
- +1 2146120000
- Auditors
- Deloitte & Touche LLP
Upcoming Events for TSHA
Taysha Gene Therapies Inc Annual Shareholders Meeting
Taysha Gene Therapies Inc Annual Shareholders Meeting
Q2 2025 Taysha Gene Therapies Inc Earnings Release
Similar to TSHA
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
Aardvark Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
FAQ
What is the Taysha Gene Therapies share price?
As of Today at 23:36 UTC, shares in Taysha Gene Therapies are trading at $2.58. This share price information is delayed by 15 minutes.
How has the Taysha Gene Therapies share price performed this year?
Shares in Taysha Gene Therapies last closed at $2.58 and the price had moved by over the past 365 days. In terms of relative price strength the Taysha Gene Therapies share price has underperformed the S&P500 Index by -9.83% over the past year.
What are the analyst and broker recommendations for Taysha Gene Therapies?
The overall consensus recommendation for Taysha Gene Therapies is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Taysha Gene Therapies dividend yield?
Taysha Gene Therapies does not currently pay a dividend.
Does Taysha Gene Therapies pay a dividend?
Taysha Gene Therapies does not currently pay a dividend.
When does Taysha Gene Therapies next pay dividends?
Taysha Gene Therapies does not currently pay a dividend.
How do I buy Taysha Gene Therapies shares?
To buy shares in Taysha Gene Therapies you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Taysha Gene Therapies?
As of the previous close price of $2.58, shares in Taysha Gene Therapies had a market capitalisation of $529.04m.
Where are Taysha Gene Therapies shares listed?
Here are the trading details for Taysha Gene Therapies:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: TSHA
What kind of share is Taysha Gene Therapies?
Based on an overall assessment of its quality, value and momentum Taysha Gene Therapies is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Taysha Gene Therapies share price forecast for 2025?
The analyst consensus target price for shares in Taysha Gene Therapies is $6.75. That is 161.63% above the last closing price of $2.58.
Analysts covering Taysha Gene Therapies currently have a consensus Earnings Per Share (EPS) forecast of -$0.37 for the next financial year.
Find out moreWhat is the trend in the Taysha Gene Therapies share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Taysha Gene Therapies. Over the past six months, its share price has outperformed the S&P500 Index by +69.4%.
As of the last closing price of $2.58, shares in Taysha Gene Therapies were trading +34.5% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Taysha Gene Therapies PE Ratio?
The Taysha Gene Therapies PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $2.58.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Taysha Gene Therapies?
Taysha Gene Therapies' management team is headed by:
- Ra Session - PRE
- Kamran Alam - CFO
- Suyash Prasad - OTH
- Phillip Donenberg - IND
- Paul Manning - IND
- Sukumar Nagendran - IND
- Sean Nolan - IND
- Kathleen Reape - IND
- Laura Sepp-Lorenzino - IND